

Jeffrey A Tice

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112540/publications.pdf>

Version: 2024-02-01

68
papers

4,649
citations

172386

29
h-index

138417

58
g-index

70
all docs

70
docs citations

70
times ranked

5637
citing authors

#	ARTICLE	IF	CITATIONS
1	Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. <i>Journal of the National Cancer Institute</i> , 2022, 114, 676-685.	3.0	18
2	The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 385-394.	2.2	11
3	Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. <i>JAMA Network Open</i> , 2022, 5, e222440.	2.8	21
4	Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting. <i>MHealth</i> , 2021, 7, 0-0.	0.9	3
5	The effectiveness and value of novel treatments for cystic fibrosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 276-280.	0.5	4
6	Endogenous Progestogens and Colorectal Cancer Risk among Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1100-1105.	1.1	3
7	The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 528-532.	0.5	1
8	Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. <i>Npj Breast Cancer</i> , 2021, 7, 78.	2.3	12
9	Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. <i>Npj Breast Cancer</i> , 2021, 7, 102.	2.3	4
10	Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B ^{1/4} FIT Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2030-2037.	1.1	2
11	The effectiveness and value of belimumab and voclosporin for lupus nephritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1495-1499.	0.5	2
12	Comparing Mammographic Density Assessed by Digital Breast Tomosynthesis or Digital Mammography: The Breast Cancer Surveillance Consortium. <i>Radiology</i> , 2021, , 204579.	3.6	10
13	The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 528-532.	0.5	0
14	Medications for Primary Prevention of Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 291.	3.8	17
15	Breast Cancer Population Attributable Risk Proportions Associated with Body Mass Index and Breast Density by Race/Ethnicity and Menopausal Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2048-2056.	1.1	41
16	Vitamin D Does Not Prevent Cancer or Cardiovascular Disease: The VITAL Trial. <i>Journal of General Internal Medicine</i> , 2020, , 1.	1.3	14
17	Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. <i>JAMA Network Open</i> , 2020, 3, e203645.	2.8	23
18	Abstract 2359: Endogenous progestogens and colorectal cancer risk among postmenopausal women. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucef vs Chemotherapy for Treatment of B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e190035.	2.8	72
20	Validation of the breast cancer surveillance consortium model of breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 519-523.	1.1	55
21	An Intervention Tool to Increase Patient-Physician Discussion of Lifestyle Risk Factors for Breast Cancer. <i>Journal of Women's Health</i> , 2019, 28, 1468-1475.	1.5	5
22	Abstract 589: Circulating progesterone is associated with increased postmenopausal breast cancer risk: B-FIT cohort. , 2019, , .		1
23	Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. <i>JAMA Internal Medicine</i> , 2018, 178, 494.	2.6	36
24	Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. <i>JAMA Pediatrics</i> , 2018, 172, 1161.	3.3	69
25	Supplemental Breast Cancer Screening: A Density Conundrum. <i>Journal of General Internal Medicine</i> , 2017, 32, 593-594.	1.3	3
26	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw290.	3.0	171
27	Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 220-225.	0.5	67
28	Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw276.	3.0	55
29	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 748.	3.8	130
30	Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 603-612.	1.1	22
31	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. <i>PLoS ONE</i> , 2017, 12, e0168601.	1.1	16
32	Screening for Breast Cancer in Women With Dense Breasts. , 2016, , 241-263.		0
33	Effectiveness and Value of Integrating Behavioral Health Into Primary Care. <i>JAMA Internal Medicine</i> , 2016, 176, 691.	2.6	30
34	Breast cancer risk prediction using a clinical risk model and polygenic risk score. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 513-525.	1.1	129
35	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 743.	3.8	286
36	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels. <i>JAMA Internal Medicine</i> , 2016, 176, 107.	2.6	41

#	ARTICLE	IF	CITATIONS
37	Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the Bâ¼FIT Cohort. Hormones and Cancer, 2016, 7, 49-64.	4.9	39
38	Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Internal Medicine, 2016, 176, 65.	2.6	118
39	Identifying Women With Dense Breasts at High Risk for Interval Cancer. Annals of Internal Medicine, 2015, 162, 673-681.	2.0	215
40	One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 889-897.	1.1	30
41	Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1419-1422.	1.1	18
42	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. Journal of the National Cancer Institute, 2015, 107, .	3.0	174
43	Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1. JAMA Internal Medicine, 2015, 175, 1559.	2.6	9
44	The Effect of Change in Body Mass Index on Volumetric Measures of Mammographic Density. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1724-1730.	1.1	26
45	Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 3137-3143.	0.8	170
46	Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial. Breast, 2015, 24, 758-766.	0.9	25
47	The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir for Chronic Hepatitis C Virus Infection. JAMA Internal Medicine, 2014, 174, 1170.	2.6	17
48	Estrogen metabolism and breast cancer risk among postmenopausal women: a caseâ€“cohort study within B-FIT. Carcinogenesis, 2014, 35, 346-355.	1.3	57
49	Abstract 940: The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model. , 2014, , .		0
50	Abstract 1603: Estrogen metabolites and colorectal cancer risk in postmenopausal women in the Breast and Bone Follow-up to the Fracture Intervention Trial (Bâ¼FIT). , 2014, , .		0
51	Benign Breast Disease, Mammographic Breast Density, and the Risk of Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 1043-1049.	3.0	99
52	Abstract B86: Estrogen metabolism and postmenopausal breast cancer risk in the Bâ¼FIT cohort. Cancer Prevention Research, 2012, 5, B86-B86.	0.7	0
53	The Vital Amines: Too Much of a Good Thing?. Archives of Internal Medicine, 2010, 170, 1631-3.	4.3	5
54	Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk. Journal of the National Cancer Institute, 2009, 101, 384-398.	3.0	226

#	ARTICLE	IF	CITATIONS
55	Mammographic density as a marker of breast cancer risk?. Current Breast Cancer Reports, 2009, 1, 175-180.	0.5	0
56	Screening and Prevention of Breast Cancer in Primary Care. Primary Care - Clinics in Office Practice, 2009, 36, 533-558.	0.7	24
57	Full-field digital mammography compared with screen-film mammography in the detection of breast cancer: rays of light through DMIST or more fog?. Breast Cancer Research and Treatment, 2008, 107, 157-165.	1.1	11
58	Introduction. Journal of General Internal Medicine, 2008, 23, 1-1.	1.3	20
59	Gastric Banding or Bypass? A Systematic Review Comparing the Two Most Popular Bariatric Procedures. American Journal of Medicine, 2008, 121, 885-893.	0.6	407
60	Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model. Annals of Internal Medicine, 2008, 148, 337.	2.0	450
61	Risk Factors for Mortality in Middle-aged Women. Archives of Internal Medicine, 2006, 166, 2469.	4.3	59
62	Prospective Breast Cancer Risk Prediction Model for Women Undergoing Screening Mammography. Journal of the National Cancer Institute, 2006, 98, 1204-1214.	3.0	399
63	Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population. Breast Cancer Research and Treatment, 2005, 94, 115-122.	1.1	219
64	Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 324-328.	1.1	58
65	The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. American Journal of Medicine, 2003, 114, 199-205.	0.6	82
66	Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study. JAMA - Journal of the American Medical Association, 2003, 290, 207.	3.8	230
67	Cost-effectiveness of Homocysteine-Lowering Therapy to Prevent Coronary Heart Disease—Reply. JAMA - Journal of the American Medical Association, 2002, 287, 191.	3.8	0
68	Relation of Serum Ascorbic Acid to Mortality Among US Adults. Journal of the American College of Nutrition, 2001, 20, 255-263.	1.1	86